Suppr超能文献

相似文献

1
Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability.
Mol Cancer Ther. 2010 Oct;9(10):2700-13. doi: 10.1158/1535-7163.MCT-10-0645.
4
Antibody-DM1 conjugates as cancer therapeutics.
Cancer Lett. 2011 Aug 28;307(2):113-8. doi: 10.1016/j.canlet.2011.03.017. Epub 2011 Apr 9.
5
High-affinity accumulation of a maytansinoid in cells via weak tubulin interaction.
PLoS One. 2015 Feb 11;10(2):e0117523. doi: 10.1371/journal.pone.0117523. eCollection 2015.
6
Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
Bioconjug Chem. 2017 May 17;28(5):1371-1381. doi: 10.1021/acs.bioconjchem.7b00062. Epub 2017 Apr 13.
7
In vitro characterization of the drug-drug interaction potential of catabolites of antibody-maytansinoid conjugates.
Drug Metab Dispos. 2012 Oct;40(10):1927-34. doi: 10.1124/dmd.112.046169. Epub 2012 Jun 29.
8
Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism.
Bioconjug Chem. 2011 Apr 20;22(4):728-35. doi: 10.1021/bc100498q. Epub 2011 Mar 10.

引用本文的文献

2
Antibody-drug conjugates in breast cancer: current evidence and future directions.
Exp Hematol Oncol. 2025 Mar 20;14(1):41. doi: 10.1186/s40164-025-00632-9.
3
Folate receptor alpha for cancer therapy: an antibody and antibody-drug conjugate target coming of age.
MAbs. 2025 Dec;17(1):2470309. doi: 10.1080/19420862.2025.2470309. Epub 2025 Mar 5.
4
Intraepithelial corneal deposits associated with Mirvetuximab soravtansine use for platinum-resistant ovarian cancer.
Am J Ophthalmol Case Rep. 2025 Feb 4;38:102271. doi: 10.1016/j.ajoc.2025.102271. eCollection 2025 Jun.
7
New hopes and promises in the treatment of ovarian cancer focusing on targeted treatment-a narrative review.
Front Pharmacol. 2024 Jun 14;15:1416555. doi: 10.3389/fphar.2024.1416555. eCollection 2024.
9
Understanding the promising role of antibody drug conjugates in breast and ovarian cancer.
Heliyon. 2023 Oct 30;9(11):e21425. doi: 10.1016/j.heliyon.2023.e21425. eCollection 2023 Nov.
10
Therapeutic strategies targeting folate receptor α for ovarian cancer.
Front Immunol. 2023 Aug 30;14:1254532. doi: 10.3389/fimmu.2023.1254532. eCollection 2023.

本文引用的文献

2
Determination of microtubule dynamic instability in living cells.
Methods Cell Biol. 2010;97:1-14. doi: 10.1016/S0091-679X(10)97001-5.
4
Antibody-maytansinoid conjugates designed to bypass multidrug resistance.
Cancer Res. 2010 Mar 15;70(6):2528-37. doi: 10.1158/0008-5472.CAN-09-3546. Epub 2010 Mar 2.
6
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.
Cancer Res. 2008 Nov 15;68(22):9280-90. doi: 10.1158/0008-5472.CAN-08-1776.
7
Suppression of microtubule dynamic instability and turnover in MCF7 breast cancer cells by sulforaphane.
Carcinogenesis. 2008 Dec;29(12):2360-8. doi: 10.1093/carcin/bgn241. Epub 2008 Oct 23.
8
Detection of GTP-tubulin conformation in vivo reveals a role for GTP remnants in microtubule rescues.
Science. 2008 Nov 28;322(5906):1353-6. doi: 10.1126/science.1165401. Epub 2008 Oct 16.
9
How do microtubule-targeted drugs work? An overview.
Curr Cancer Drug Targets. 2007 Dec;7(8):730-42. doi: 10.2174/156800907783220417.
10
Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Acc Chem Res. 2008 Jan;41(1):98-107. doi: 10.1021/ar700108g. Epub 2007 Aug 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验